A tumor-penetrating peptide, iRGD, was synthesized by LifeTein. It was found that iRGD improves tumor-specific penetration of intraperitoneal compounds and enhances intraperitoneal chemotherapy (IPC) in mice. This penetration was tumor-specific. When the FITC was attached to iRGD and mixed with nanoparticles, the mixture could penetrate into fresh human peritoneal metastasis explants. The evidence proved that the LifeTein iRGD enhanced intratumoral entry. The intraperitoneal iRGD co-administration is a simple and effective strategy to facilitate tumor detection and potential application for therapeutic improvement.
LifeTein’s Peptide: iRGD